Kinfo
Kymera Therapeutics Inc. logo

Kymera Therapeutics Inc.

KYMRNASDAQHealthcare·US · USD
$131.73
+3.61 (+2.82%)
Prices as of November 6, 2026 · market closed

Price

Key statistics

Valuation
Market cap11.25B USD
Enterprise value10.35B USD
Trailing P/E-35.69
Forward P/E-25.74
PEG ratio1.03
Price / sales110.00
Price / book6.96
Profitability
Gross margin0.00%
Operating margin-396.04%
Profit margin0.00%
Return on assets-17.64%
Return on equity-27.29%
Income (TTM)
Revenue102.23M USD
Gross profit-327.75M USD
EBITDA-398.38M USD
Net income-349.42M USD
Diluted EPS-$3.64
Rev. growth (YoY)89.15%
Balance sheet
Total cash971.21M USD
Total debt76.60M USD
Debt / equity4.74
Current ratio11.13
Book value / share$18.92
Cash flow (TTM)
Operating cash flow-287.56M USD
Levered free cash flow-164.68M USD
Shares & price
Shares outstanding82.79M
Float68.26M
Held by institutions116.99%
Beta2.03
50-day MA$115.67
200-day MA$97.91
52-week high$138.00
52-week low$58.87
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-10-29-1.27-1.32−3.94%2026-08-05-0.74-0.62+16.22%2026-05-080.110.13+18.18%2026-04-30-0.86-0.71+17.44%2026-02-26-0.77-0.98−27.27%
About Kymera Therapeutics Inc.

Kymera Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines that use targeted protein degradation to address disease-causing proteins. The company’s work centers on harnessing the body’s natural protein recycling systems to create oral therapies designed for conditions that are difficult to treat with conventional approaches. Its current programs span immunology, inflammation, and oncology, with research aimed at diseases such as atopic dermatitis, hidradenitis suppurativa, autoimmune disorders, and certain cancers. Kymera Therapeutics Inc. operates through a differentiated drug-discovery platform that supports both internal pipeline development and strategic research collaborations. Headquartered in Watertown, Massachusetts, the company plays a specialized role in the biotechnology market by advancing novel treatment approaches for serious diseases.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Nello Mainolfi M.D., Ph.D.
Employees
285
Headquarters
Watertown, MA, United States

Frequently asked questions about Kymera Therapeutics Inc.